Latest Articles




Pre-result build up? The “big catalyst” in 2023

Sep 02, 2022

Our biotech Investment and 2021 Biotech Pick of the Year, Dimerix (ASX:DXB), has been busy this year working towards its all important Phase 3 trial and first interim results. After our initial entry at 20c in August 2021, our Investment in DXB is currently sitting below that price at 14.5 cents.

DXB Recruits First Patient, Gets FDA IND Approval

Jun 01, 2022

Our 2021 Biotech Pick of the Year, Dimerix (ASX:DXB), yesterday recruited its first patient for its Phase 3 FSGS trial - a big step forward towards our #1 Objective for the company.

DXB: Making Strong Progress on “Main Bet,” Side Bet #2 Paused

Feb 28, 2022

Our 2021 Biotech Pick of the Year Dimerix (ASX:DXB) released its half year report last Thursday, updating investors on ethics approvals for its Phase III clinical trial for FSGS (a rare kidney disease) and closing in on important milestones for TWO of its Phase III COVID-19 studies.

New Portfolio Addition: Arovella Therapeutics

Feb 18, 2022

Today we are finally announcing a new investment in the Next Investors portfolio. Arovella Therapeutics (ASX:ALA) is a small ASX biotech going after a unique solution to the scourge of cancer - with cutting edge technology licensed from some of the foremost cancer research institutions - and has attracted big names to the project.



Earlier than Expected - DXB Gets First Regulatory Approval in Europe.

Feb 01, 2022

Dimerix (ASX:DXB) just delivered significant progress on its Phase III Clinical Trial for FSGS, with the first EU regulatory approval given for DXB’s kidney disease study in Denmark... earlier than expected.

DXB kidney disease treatment Phase III trial officially begins

Oct 21, 2021

Today DXB announced that the ethics approval was granted for its Phase III clinical trial on kidney disease FSGS, marking the “official start” of the trial.

DXB to run a Phase III COVID-19 Study in Australia

Oct 15, 2021

Dimerix (ASX:DXB) is moving fast with its Covid-19 trials, and today announced that this COVID-19 Phase III Study will expand to Australia.

DXB announces approval for Phase III COVID-19 trials in India

Sep 24, 2021

The main drug regulator in India has recommended approval for Dimerix Ltd's (ASX:DXB) Phase 3 clinical trials on its COVID-19 treatment for patients with respiratory complications.

How we invest in early stage biotech companies

Sep 17, 2021

What does it mean for retail investors to invest in an early stage biotech company? We cover biotech investing from inception to commercialisation, the different stages of clinical trials and the investing risks involved with early stage biotechs.

DXB kicks off Phase 3 clinical trials - Ethics approval lodged

Aug 26, 2021

Yesterday Dimerix (ASX:DXB) announced its first “ethics submission” in Australia. Once approved, the patient recruitment process can begin for the Phase 3 trials. We will provide our commentary at every step in the process.